HK1077306A1 - Ocular gene therapy - Google Patents

Ocular gene therapy

Info

Publication number
HK1077306A1
HK1077306A1 HK05110989.7A HK05110989A HK1077306A1 HK 1077306 A1 HK1077306 A1 HK 1077306A1 HK 05110989 A HK05110989 A HK 05110989A HK 1077306 A1 HK1077306 A1 HK 1077306A1
Authority
HK
Hong Kong
Prior art keywords
choroidal neovascularization
gene therapy
ocular gene
vivo
individual
Prior art date
Application number
HK05110989.7A
Other languages
English (en)
Inventor
Peter Anthony Campochiaro
Michael Kaleko
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1077306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1077306A1 publication Critical patent/HK1077306A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK05110989.7A 2002-08-28 2005-12-01 Ocular gene therapy HK1077306A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40647002P 2002-08-28 2002-08-28
PCT/EP2003/009497 WO2004020469A2 (en) 2002-08-28 2003-08-27 Ocular gene therapy

Publications (1)

Publication Number Publication Date
HK1077306A1 true HK1077306A1 (en) 2006-02-10

Family

ID=31978303

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05110989.7A HK1077306A1 (en) 2002-08-28 2005-12-01 Ocular gene therapy

Country Status (12)

Country Link
US (1) US20070104684A1 (xx)
EP (1) EP1534751B1 (xx)
JP (1) JP4612417B2 (xx)
CN (2) CN101637611A (xx)
AT (1) ATE464321T1 (xx)
AU (1) AU2003258675B2 (xx)
CA (1) CA2496820A1 (xx)
DE (1) DE60332122D1 (xx)
HK (1) HK1077306A1 (xx)
IL (1) IL166950A (xx)
NZ (1) NZ538958A (xx)
WO (1) WO2004020469A2 (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174861B1 (en) 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
ES2245042T3 (es) * 1997-09-24 2005-12-16 The Regents Of The University Of California Vectores de lentivirus de no primates y sistemas de empaquetamiento.
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
JP2003531609A (ja) * 2000-05-01 2003-10-28 ノバルティス アクチエンゲゼルシャフト 目に関する形質導入用ベクターおよび遺伝子治療を目的とするその用途
AU2001272932A1 (en) * 2000-06-02 2001-12-17 Entremed, Inc Angiostatin and endostatin binding proteins and methods of use
AU2002224403A1 (en) * 2000-10-13 2002-04-22 Entremed, Inc Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
US20020183253A1 (en) * 2001-02-22 2002-12-05 Brazzell Romulus Kimbro Method of treating ocular neovascularization
EP1476581A4 (en) * 2002-02-04 2006-06-21 Novartis Ag GENERIC TRANSFER SYSTEM BASED ON RECOMBINANT IMPLANT IMMUNE VIRUS
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
WO2004028635A1 (en) * 2002-09-27 2004-04-08 Novartis Ag Ocular gene therapy

Also Published As

Publication number Publication date
CN1708513A (zh) 2005-12-14
WO2004020469A3 (en) 2004-04-29
EP1534751A2 (en) 2005-06-01
US20070104684A1 (en) 2007-05-10
WO2004020469A2 (en) 2004-03-11
AU2003258675B2 (en) 2009-03-26
CA2496820A1 (en) 2004-03-11
JP4612417B2 (ja) 2011-01-12
NZ538958A (en) 2006-09-29
DE60332122D1 (de) 2010-05-27
IL166950A (en) 2011-04-28
ATE464321T1 (de) 2010-04-15
JP2006516112A (ja) 2006-06-22
EP1534751B1 (en) 2010-04-14
CN100526332C (zh) 2009-08-12
CN101637611A (zh) 2010-02-03
AU2003258675A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
TW200502385A (en) Modulation of forkhead box o1a expression
MX2010003774A (es) Formulaciones oftalmicas acuosas.
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2005099715A3 (en) Treatment of ophthalmic conditions with mineralcorticoids
SG166672A1 (en) Methods of down regulating target gene expression in vivo by introduction of interfering rna
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
TW200637522A (en) Skin treatment articles and methods
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
HK1145070A1 (en) Therapeutic use of a growth factor, metrnl
MX344587B (es) Metodo para incrementar la estabilidad in vitro e in vivo de enzimas asociadas al transtorno lisosomal.
TW200637574A (en) Treatment method
WO2008067040A3 (en) Method of detecting ocular diseases and pathologic conditions and treatment of same
GB0416508D0 (en) Therapeutic agents
EP0859636A4 (en) HYALURONIC ACID USED AS A DNA CARRIER FOR GENE THERAPY AND ANTI-SENSE DNA OF THE VASCULAR ENDOTHELIUM GROWTH FACTOR FOR THE TREATMENT OF ABNORMAL RETINA VASCULARIZATION
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
HK1077306A1 (en) Ocular gene therapy
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
WO2006004774A3 (en) Laulimalide analogues as therapeutic agents
MX2009005503A (es) Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
MX2010004313A (es) Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220827